Novo Nordisk stock adds new ObesityWeek data catalyst
Published on 10/29/2026 at 17:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSNew obesity data ahead
- Novo Nordisk will present new analyses from its obesity portfolio at the upcoming ObesityWeek meeting.
- The program covers real-world Wegovy treatment, investigational CagriSema and pediatric semaglutide research.
- The company describes CagriSema and the pediatric use as investigational rather than approved treatments.
Novo Nordisk announced on October 29, 2026, that it will present new data from its obesity portfolio at ObesityWeek 2026. The announcement, published by PR Newswire, adds a fresh pipeline and commercial-data catalyst to the investment case. The company said the program covers 26 abstracts at the meeting in Washington, D.C., from November 14 to 17.
What has changed since our last report
The latest announcement expands the focus beyond the analyst-target discussion and second-quarter figures covered in the most recent relevant report on October 27. Novo Nordisk said the presentations will include real-world treatment experience with the Wegovy pill and injection, including data from telehealth settings.
Further items include new analyses from the investigational CagriSema REDEFINE program and research on investigational semaglutide injection in children aged 6 to under 12. The company also plans to present results from the REDEFINE 9 study of lower CagriSema doses and post-hoc analyses from REDEFINE 1.
Pipeline signal, not approval news
For investors, the announcement is a timetable and data-disclosure signal rather than a new regulatory approval. Novo Nordisk states that CagriSema is not approved in the United States or elsewhere, while investigational semaglutide injection is not approved in the United States for children under 12.
At Lang & Schwarz, Novo Nordisk traded at 34.78 euros on October 29, 2026, at 16:07:30 Berlin time. The quote is a valid dated reference for the German listing; the company's primary listing is Nasdaq Copenhagen, where its B shares trade in Danish kroner.
The continuously updated real-time quote of Novo Nordisk stock provides the latest market reference.
Novo Nordisk stock facts
- Company: Novo Nordisk A/S
- ISIN: DK0062498333
- Price Lang & Schwarz: 34.78 euros as of October 29, 2026, 16:07:30 Berlin time
- Primary exchange: Nasdaq Copenhagen
Market context: Current market reports.
